Exciting new results from a genetic study in humans and functional studies in mice have pinpointed interleukin 23 (IL23) and its receptor as a key pathway in the pathogenesis of inflammatory bowel ...

making this subset of particular importance in the study of its pathophysiology. 12, 13 “The major drawback of the extent based classification system was clearly identified to be instability of ...

Inflammatory bowel disease is a chronic condition of unknown origin characterized by severe inflammation and mucosal destruction in the intestine. There are two main forms: Crohn s disease ...

Armed with positive data from a phase 2b trial, Teva and Sanofi have decided to push their anti-TL1A antibody duvakitug into a phase 3 programme in inflammatory bowel disease (IBD). The results of ...

Bristol Myers Squibb announces positive data from POETYK PSO LTE trial of Sotyktu to treat moderate-to-severe plaque psoriasis: Princeton, New Jersey Tuesday, February 18, 2025, 1 ...

Tokyo, Japan and Cambridge, UK, 14 February 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) provides an update on operational activities and reports its consolidated results for the ...

Bristol Myers Squibb today announced new five-year results from the POETYK PSO long-term extension (LTE) trial of Sotyktu (deucravacitinib) treatment in adult patients with moderate-to-severe plaque ...

Other treatments may include fluids, electrolytes, antibiotics, and nutrition support. The pressure associated with IBD may be from diarrhea or constipation caused by the disease. It could also be ...

Diagnosis and management of non-alcoholic fatty liver disease. Postgrad Med J. 2019;95(1124):314-22. National Institute of Diabetes and Digestive and Kidney Diseases. Eating, diet, and nutrition for ...